Sign In
Buy SCPH
$5.67
+0 (+0%)
At Close: Jan 06, 2026
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Thursday, 05'th Oct 2023
BURLINGTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercial
scPharmaceuticals: Furoscix, Charting A Bright Future With FDA's Nod For CKD
12:40am, Wednesday, 27'th Sep 2023
Positive FDA feedback for Furoscix's label expansion into chronic kidney disease signals the potential for significant market growth. Introduction of a higher concentration auto-injector formulation o
scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives
08:00am, Tuesday, 19'th Sep 2023
Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients
Sizing Up scPharmaceuticals
02:13pm, Wednesday, 13'th Sep 2023
Today, we take our first look at scPharmaceuticals Inc., which has received positive analyst commentary but has a large short position in the stock. The company just launched its franchise product FUR
scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08:00am, Tuesday, 05'th Sep 2023
BURLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to opti
scPharmaceuticals Inc. (SCPH) Q2 2023 Earnings Call Transcript
10:38pm, Thursday, 10'th Aug 2023
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants PJ Kelleher - Investor Relations John Tucker - Chief Executive Officer Steve Pars
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates
07:01pm, Thursday, 10'th Aug 2023
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.35 per share a year ago.
scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023
08:00am, Thursday, 03'rd Aug 2023
BURLINGTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optim
scPharmaceuticals, Inc. (SCPH) Loses -21.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:21am, Tuesday, 18'th Jul 2023
The heavy selling pressure might have exhausted for scPharmaceuticals, Inc. (SCPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall St
scPharmaceuticals: Oversold Territory, Drug Launch Still Looks Robust
11:05pm, Thursday, 29'th Jun 2023
scPharmaceuticals' Furoscix dose-filling rates increased by 55% month over month in May. Despite the lower figures than market expectations, SCPH stock price has fallen, but we expect an inflection po
scPharmaceuticals to Present at the Jefferies Healthcare Conference
08:00am, Wednesday, 31'st May 2023
BURLINGTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimi
scPharmaceuticals: Furoscix Firing On All Cylinders In Q1, Bullish Than Ever
12:15am, Saturday, 20'th May 2023
SCPH's Furoscix, despite just launching, defied street consensus with an impressive $2.1M revenue in 1Q23, indicating a promising ramp trajectory. Witnessing a substantial increase in Furoscix's presc
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
06:59pm, Wednesday, 10'th May 2023
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.28 per share a year ago.
scPharmaceuticals Inc. (SCPH) Q4 2022 Earnings Call Transcript
08:11pm, Wednesday, 22'nd Mar 2023
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - CEO Rachael Nokes - CFO Steve Parsons
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22
08:00am, Wednesday, 15'th Mar 2023
Management to host conference call and webcast at 4:30 p.m. ET
